Spectrum Pharmaceuticals Presents Data at the AACR-NCI-EORTC Meeting That SPI-1620 Significantly Enhances the Anti-Tumor Efficacy of Paclitaxel in Breast Tumor Model
* Data is published in the current edition of a peer-reviewed journal,
Breast Cancer Research and Treatment
* SPI-1620 transiently increases blood flow to tumors
* Selectively enhances paclitaxel delivery to tumors
* Enhances anti-tumor efficacy in breast tumor animal models
IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Spectrum
Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that data from a study conducted by Dr. N.V. Rajeshkumar, from the University of Illinois at Chicago, on SPI-1620, was presented at the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications Meeting in Philadelphia, Pennsylvania.
Data published in the abstract clearly shows that SPI-1620 significantly enhances the efficacy of paclitaxel. Animals treated with SPI-1620 followed by treatment with paclitaxel 15 minutes later showed better efficacy when
compared to control animals in terms of tumor volume, progression and complete regression.
In fact, only SPI-1620-treated groups showed complete regression.
The study demonstrates that SPI-1620 could be used as a tumor selective vasodilator to enhance delivery and efficacy of paclitaxel and other chemotherapeutic agents.
In addition, this information is contained in the current issue of a peer reviewed journal, "Breast Cancer Research and Treatment," which published a research article entitled "Endothelin B receptor agonist, IRL-1620, enhances
the anti-tumor efficacy of paclitaxel in breast tumor rats."
"We are pleased to announce both the presentation at the AACR-NCI-EORTC meeting and the publication of this proof-of-principle data in a reputed journal," stated Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer
and President. "In addition to the enhanced delivery of paclitaxel to breast tumors as shown in this publication, we now have evidence that this approach is applicable to the delivery of other cancer drugs in other cancer models.
We look forward to moving this product into the clinic in 2006."
About SPI-1620
SPI-1620 is an endothelin B agonist that stimulates receptors on endothelial cells, the innermost layer of cells lining the blood vessels, to selectively dilate blood vessels in the tumor, resulting in a transient increase in blood flow and a consequent increase in the delivery of anti-cancer drugs, such as paclitaxel, to the tumor, as shown in animal
studies to date.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a specialty pharmaceutical company engaged in the business of acquiring, developing and commercializing prescription drug products for the treatment of cancer and other unmet medical needs. By leveraging its operational flexibility and regulatory proficiency, and using
the extensive research and development capabilities of its strategic alliance partners, Spectrum has built a diversified portfolio of proprietary and generic drug products in various stages of development and regulatory approval. For more information, please visit our website at spectrumpharm.com.
Contact:
Laurie Little
Sr. Director, Investor Relations
(949) 743-9216
prnewswire.com
Comment:
From bad memory - I think there are other companies
going after Endothelin B / C / D ?
But maybe my *context* is misplaced. |
